{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T22:23:23Z","timestamp":1791843803164,"version":"4.3.4"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100010104","name":"Tianjin Medical University","doi-asserted-by":"publisher","award":["TJYXZDXK-012A"],"award-info":[{"award-number":["TJYXZDXK-012A"]}],"id":[{"id":"10.13039\/501100010104","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100016346","name":"Second Hospital of Tianjin Medical University","doi-asserted-by":"publisher","award":["KY2020K048"],"award-info":[{"award-number":["KY2020K048"]}],"id":[{"id":"10.13039\/501100016346","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019065","name":"Tianjin Municipal Science and Technology Program","doi-asserted-by":"publisher","award":["KJ20034"],"award-info":[{"award-number":["KJ20034"]}],"id":[{"id":"10.13039\/501100019065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Pathology"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.humpath.2024.105704","type":"journal-article","created":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T19:13:21Z","timestamp":1733771601000},"page":"105704","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["PD-L1 expression and immune infiltration across molecular subtypes of endometrial cancer: An integrative-analysis of molecular classification and immune subtypes"],"prefix":"10.1016","volume":"154","author":[{"given":"Yanhui","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baohui","family":"Ju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runfen","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7351-8933","authenticated-orcid":false,"given":"Jianghua","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.humpath.2024.105704_bib1","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Cancer Genome Atlas Research","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.humpath.2024.105704_bib2","series-title":"Female genital tumours","article-title":"World Health organization classification of tumours","year":"2020"},{"key":"10.1016\/j.humpath.2024.105704_bib3","doi-asserted-by":"crossref","first-page":"e85","DOI":"10.3802\/jgo.2023.34.e85","article-title":"Endometrial cancer staging subcommittee FWsCC. FIGO staging of endometrial cancer: 2023","volume":"34","author":"Berek","year":"2023","journal-title":"J Gynecol Oncol"},{"key":"10.1016\/j.humpath.2024.105704_bib4","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1001\/jamaoncol.2020.4515","article-title":"Clinical activity and safety of the anti-programmed death 1 monoclonal antibody dostarlimab for patients with recurrent or advanced mismatch repair-deficient endometrial cancer: a nonrandomized phase 1 clinical trial","volume":"6","author":"Oaknin","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.humpath.2024.105704_bib5","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1111\/cas.15436","article-title":"Lenvatinib plus pembrolizumab in Japanese patients with endometrial cancer: results from Study 309\/KEYNOTE-775","volume":"113","author":"Yonemori","year":"2022","journal-title":"Cancer Sci"},{"key":"10.1016\/j.humpath.2024.105704_bib6","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004338","article-title":"Phase II trial of efficacy, safety and biomarker analysis of sintilimab plus anlotinib for patients with recurrent or advanced endometrial cancer","volume":"10","author":"Wei","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.humpath.2024.105704_bib7","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1056\/NEJMoa2216334","article-title":"Dostarlimab for primary advanced or recurrent endometrial cancer","volume":"388","author":"Mirza","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.humpath.2024.105704_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14163911","article-title":"PD-L1 expression in endometrial cancer and its association with clinicopathological features: a systematic review and meta-analysis","volume":"14","author":"Mamat Yusof","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.humpath.2024.105704_bib9","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nature21349","article-title":"Elements of cancer immunity and the cancer-immune set point","volume":"541","author":"Chen","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.humpath.2024.105704_bib10","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15072042","article-title":"Immune environment and immunotherapy in endometrial carcinoma and cervical tumors","volume":"15","author":"Laine","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.humpath.2024.105704_bib11","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1158\/0008-5472.CAN-15-0255","article-title":"Classifying cancers based on T-cell infiltration and PD-L1","volume":"75","author":"Teng","year":"2015","journal-title":"Cancer Res"},{"issue":"Suppl 1","key":"10.1016\/j.humpath.2024.105704_bib12","doi-asserted-by":"crossref","first-page":"S123","DOI":"10.1097\/PGP.0000000000000488","article-title":"Interpretation of P53 immunohistochemistry in endometrial carcinomas: toward increased reproducibility","volume":"38","author":"Kobel","year":"2019","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.humpath.2024.105704_bib13","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-17204-5","article-title":"QuPath: open source software for digital pathology image analysis","volume":"7","author":"Bankhead","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.humpath.2024.105704_bib14","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1378844","article-title":"Maturation of tertiary lymphoid structures and recurrence of stage II and III colorectal cancer","volume":"7","author":"Posch","year":"2018","journal-title":"OncoImmunology"},{"key":"10.1016\/j.humpath.2024.105704_bib15","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/PAS.0000000000001395","article-title":"PD-L1 expression in endometrial carcinoma cells and intratumoral immune cells: differences across histologic and TCGA-based molecular subgroups","volume":"44","author":"Pasanen","year":"2020","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.humpath.2024.105704_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.anndiagpath.2023.152137","article-title":"The expression of programmed death-ligand 1 and programmed death-ligand 2 in endometrial carcinosarcoma: correlation with mismatch repair protein expression status, tumor-infiltrating lymphocyte infiltration, and clinical outcomes","volume":"65","author":"Atilgan","year":"2023","journal-title":"Ann Diagn Pathol"},{"key":"10.1016\/j.humpath.2024.105704_bib17","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1080\/15321819.2021.1981377","article-title":"Immune checkpoint proteins (PD-L1 and CTLA-4) in endometrial carcinoma: prognostic role and correlation with CD4(+)\/CD8(+) tumor infiltrating lymphocytes (TILs) ratio","volume":"43","author":"Khalifa","year":"2022","journal-title":"J Immunoassay Immunochem"},{"key":"10.1016\/j.humpath.2024.105704_bib18","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s12885-020-6545-9","article-title":"PD-L1 and CD4 are independent prognostic factors for overall survival in endometrial carcinomas","volume":"20","author":"Zhang","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.humpath.2024.105704_bib19","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1001\/jamaoncol.2016.2450","article-title":"Classification of advanced human cancers based on tumor immunity in the MicroEnvironment (TIME) for cancer immunotherapy","volume":"2","author":"Zhang","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.humpath.2024.105704_bib20","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1097\/PAS.0000000000001503","article-title":"PD-L1 expression and CD8+ tumor-infiltrating lymphocytes in different types of tubo-ovarian carcinoma and their prognostic value in high-grade serous carcinoma","volume":"44","author":"Chen","year":"2020","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.humpath.2024.105704_bib21","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.ygyno.2018.02.013","article-title":"Prognostic implication of programmed cell death 1 protein and its ligand expressions in endometrial cancer","volume":"149","author":"Kim","year":"2018","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.humpath.2024.105704_bib22","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1097\/PGP.0000000000000890","article-title":"Programmed death ligand 1 (PD-L1) expression and CD8 + tumor-infiltrating lymphocyte-based tumor immune microenvironment classification in gynecologic carcinosarcoma: prognostic impact and implications for therapy","volume":"42","author":"Ordner","year":"2023","journal-title":"Int J Gynecol Pathol"},{"key":"10.1016\/j.humpath.2024.105704_bib23","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1001\/jamaoncol.2015.2151","article-title":"Association of polymerase e-mutated and microsatellite-instable endometrial cancers with neoantigen load, number of tumor-infiltrating lymphocytes, and expression of PD-1 and PD-L1","volume":"1","author":"Howitt","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.humpath.2024.105704_bib24","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ygyno.2015.04.027","article-title":"Polymerase epsilon (POLE) ultra-mutated tumors induce robust tumor-specific CD4+ T cell responses in endometrial cancer patients","volume":"138","author":"Bellone","year":"2015","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.humpath.2024.105704_bib25","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.ygyno.2021.02.030","article-title":"Tumor-infiltrating lymphocytes and POLE mutation in endometrial carcinoma","volume":"161","author":"Raffone","year":"2021","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.humpath.2024.105704_bib26","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1158\/1078-0432.CCR-16-2655","article-title":"Immune microenvironment in microsatellite-instable endometrial cancers: hereditary or sporadic origin matters","volume":"23","author":"Pakish","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.humpath.2024.105704_bib27","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/s41379-018-0148-x","article-title":"Identification of a subset of microsatellite-stable endometrial carcinoma with high PD-L1 and CD8+ lymphocytes","volume":"32","author":"Crumley","year":"2019","journal-title":"Mod Pathol"},{"key":"10.1016\/j.humpath.2024.105704_bib28","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/path.5375","article-title":"p53 immunohistochemistry is an accurate surrogate for TP53 mutational analysis in endometrial carcinoma biopsies","volume":"250","author":"Singh","year":"2020","journal-title":"J Pathol"},{"key":"10.1016\/j.humpath.2024.105704_bib29","doi-asserted-by":"crossref","first-page":"4807","DOI":"10.2174\/1381612823666170714161703","article-title":"Role of the immune component of tumor microenvironment in the efficiency of cancer treatment: perspectives for the personalized therapy","volume":"23","author":"Stakheyeva","year":"2017","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.humpath.2024.105704_bib30","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/s41568-022-00466-1","article-title":"Tumour-infiltrating B cells: immunological mechanisms, clinical impact and therapeutic opportunities","volume":"22","author":"Laumont","year":"2022","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.humpath.2024.105704_bib31","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/s41571-022-00619-z","article-title":"B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome","volume":"19","author":"Fridman","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.humpath.2024.105704_bib32","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1007\/s00262-021-03093-1","article-title":"Tertiary lymphoid structures are associated with favorable survival outcomes in patients with endometrial cancer","volume":"71","author":"Qin","year":"2022","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.humpath.2024.105704_bib33","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1038\/s41467-022-29040-x","article-title":"Tertiary lymphoid structures critical for prognosis in endometrial cancer patients","volume":"13","author":"Horeweg","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.humpath.2024.105704_bib34","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.ygyno.2014.08.028","article-title":"Prognostic significance of tumor-associated macrophages in endometrial adenocarcinoma","volume":"135","author":"Kubler","year":"2014","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.humpath.2024.105704_bib35","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1136\/ijgc-2022-003772","article-title":"Update in the molecular classification of endometrial carcinoma","volume":"33","author":"Leon-Castillo","year":"2023","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.humpath.2024.105704_bib36","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005443","article-title":"Biomarkers of tumor-reactive CD4(+) and CD8(+) TILs associate with improved prognosis in endometrial cancer","volume":"10","author":"Palomero","year":"2022","journal-title":"J Immunother Cancer"}],"container-title":["Human Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817724002132?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817724002132?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T20:31:41Z","timestamp":1787257901000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0046817724002132"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":36,"alternative-id":["S0046817724002132"],"URL":"https:\/\/doi.org\/10.1016\/j.humpath.2024.105704","relation":{},"ISSN":["0046-8177"],"issn-type":[{"value":"0046-8177","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PD-L1 expression and immune infiltration across molecular subtypes of endometrial cancer: An integrative-analysis of molecular classification and immune subtypes","name":"articletitle","label":"Article Title"},{"value":"Human Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humpath.2024.105704","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105704"}}